Garen Bohlin held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Mr. Bohlin was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline). Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals (acquired by Biogen).
Prior to Syntonix, Mr. Bohlin served as Executive Vice President of Genetics Institute (acquired by American Home Products/Wyeth). Mr. Bohlin currently serves on the board of directors of Karyopharm Therapeutics, Inc. (KPTI). Previously, he served on the board of directors of Acusphere, Inc. (ACUS), Proteon Therapeutics, Inc. (PRTO), Tetraphase Pharmaceuticals, Inc. (TTPH) and several other publicly traded and privately held biotechnology companies.